In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a price target of $40.00. The company’s shares
In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a price target of $40.00. The company’s shares
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Summit Therapeutics (SMMT – Research Report). The associated price target remains the same with $45.00. Mitchell Kapoor has
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Costco (COST) reported upbeat Q4 earnings but lower-than-expected revenue
Citi downgraded Summit Therapeutics to Neutral from Buy with a price target of $23, up from $19. With the shares up 670% and now trading at a $16B market capitalization
In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a price target of $40.00. The company’s shares